Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

John Tsai, Global Head, R&D, Daiichi Sankyo

“At Daiichi Sankyo, we are focused on maximizing the potential of our DXd antibody drug conjugate portfolio through innovative combinations and strategic collaborations that support the continued advancement of our pipeline.”

John Tsai, Global Head, R&D, Daiichi Sankyo

“We are encouraged by the opportunity to explore ivonescimab in combination with Datroway to potentially deliver clinically meaningful benefit to patients.”

Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca

“Central to our strategy to transform cancer outcomes is harnessing the power of immunotherapy and antibody drug conjugate combinations to drive deeper, more durable responses.”

Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca

“We believe the combination of Datroway and ivonescimab has the potential to make a meaningful difference in multiple tumor types including lung and breast cancers.”

Maky Zanganeh, President and Co-Chief Executive Officer, Summit Therapeutics

“We believe this collaboration with Daiichi Sankyo and AstraZeneca reflects increasing conviction in ivonescimab’s potential as a foundational next-generation immunotherapy and advances our ambition for ivonescimab to become the global PD-1/VEGF partner of choice for novel combinations.”

Maky Zanganeh, President and Co-Chief Executive Officer, Summit Therapeutics

“Beginning with a phase 3 study in first-line triple negative breast cancer, this collaboration represents an important expansion of Summit’s global development program into breast cancer and a path for additional solid tumor settings.”